Simon Pedder, Ph.D.
Chief Executive Officer
Simon has a career of over 30 years in drug development and commercialization. He was recently Chief Business and Strategy Officer for Athenex. Prior he had leadership roles as; President and CEO of Cellectar Biosciences; President and CEO of Chelsea Therapeutics; Global Vice President of Oncology Pharma Business and Executive Officer at Hoffmann-LaRoche. Previous positions at Roche included Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise. Prior, he was Clinical Leader for a number of development compounds at Roche. Early in his career he was a faculty in the Department of Pharmacology in College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. During his longstanding career in pharmaceutical development, Simon had played key roles in the successful development and commercial of multiple proprietary pharmaceutical products including Tasmar®, Pegasys®, Copegus®, Northera® and Klisyri®. In addition to his Ph.D., Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor degree in Environmental Studies/Biology from the University of Waterloo, and he completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.